{"doi":"10.3390/cancers15030945","title":"Genomic Prostate Score: A New Tool to Assess Prognosis and Optimize Radiation Therapy Volumes and ADT in Intermediate-Risk Prostate Cancer","abstract":"<jats:p>Genomic classifiers such as the Genomic Prostate Score (GPS) could help to personalize treatment for men with intermediate-risk prostate cancer (I-PCa). In this study, we aimed to evaluate the ability of the GPS to change therapeutic decision making in I-PCa. Only patients in the intermediate NCCN risk group with Gleason score 3 + 4 were considered. The primary objective was to assess the impact of the GPS on risk stratification: NCCN clinical and genomic risk versus NCCN clinical risk stratification alone. We also analyzed the predictive role of the GPS for locally advanced disease (≥pT3+) and the potential change in treatment strategy. Thirty patients were tested for their GPS between November 2018 and March 2020, with the median age being 70 (45–79). Twenty-three patients had a clinical T1 stage. Eighteen patients were classified as favorable intermediate risk (FIR) based on the NCCN criteria. The median GPS score was 39 (17–70). Among the 23 patients who underwent a radical prostatectomy, Gleason score 3 + 4 was found in 18 patients. There was a significant correlation between the GPS and the percentage of a Gleason grade 4 or higher pattern in the surgical sample: correlation coefficient r = 0.56; 95% CI = 0.2–0.8; p = 0.005. In this study, the GPS combined with NCCN clinical risk factors resulted in significant changes in risk group.</jats:p>","journal":"Cancers","year":2023,"id":646583,"datarank":0.31191623125197543,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"self_citation_contribution":0.31191623125197543,"citation_network_contribution":0.0,"self_endowment_contribution":0.31191623125197543,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":7,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1684221,"name":"Kamel Debbi","orcid":null,"position":1,"is_corresponding":false},{"id":1684222,"name":"Gabriele Coraggio","orcid":null,"position":2,"is_corresponding":false},{"id":1684223,"name":"Jérome Bendavid","orcid":null,"position":3,"is_corresponding":false},{"id":1684224,"name":"Maya Nourieh","orcid":"0000-0002-4670-6477","position":4,"is_corresponding":false},{"id":1684225,"name":"Nhu Hanh To","orcid":"0000-0002-8486-9728","position":5,"is_corresponding":false},{"id":1684226,"name":"Mohamed Aziz Cherif","orcid":null,"position":6,"is_corresponding":false},{"id":1684227,"name":"Carolina Saldana","orcid":null,"position":7,"is_corresponding":false},{"id":1684228,"name":"Alexandre Ingels","orcid":null,"position":8,"is_corresponding":false},{"id":1684229,"name":"Alexandre De La Taille","orcid":null,"position":9,"is_corresponding":false},{"id":1684230,"name":"Gokoulakrichenane Loganadane","orcid":null,"position":10,"is_corresponding":false},{"id":1684220,"name":"Yazid Belkacemi","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Genomic Prostate Score: A New Tool to Assess Prognosis and Optimize Radiation Therapy Volumes and ADT in Intermediate-Risk Prostate Cancer","abstract":"<jats:p>Genomic classifiers such as the Genomic Prostate Score (GPS) could help to personalize treatment for men with intermediate-risk prostate cancer (I-PCa). In this study, we aimed to evaluate the ability of the GPS to change therapeutic decision making in I-PCa. Only patients in the intermediate NCCN risk group with Gleason score 3 + 4 were considered. The primary objective was to assess the impact of the GPS on risk stratification: NCCN clinical and genomic risk versus NCCN clinical risk stratification alone. We also analyzed the predictive role of the GPS for locally advanced disease (≥pT3+) and the potential change in treatment strategy. Thirty patients were tested for their GPS between November 2018 and March 2020, with the median age being 70 (45–79). Twenty-three patients had a clinical T1 stage. Eighteen patients were classified as favorable intermediate risk (FIR) based on the NCCN criteria. The median GPS score was 39 (17–70). Among the 23 patients who underwent a radical prostatectomy, Gleason score 3 + 4 was found in 18 patients. There was a significant correlation between the GPS and the percentage of a Gleason grade 4 or higher pattern in the surgical sample: correlation coefficient r = 0.56; 95% CI = 0.2–0.8; p = 0.005. In this study, the GPS combined with NCCN clinical risk factors resulted in significant changes in risk group.</jats:p>","is_dataset_classified":null,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"36765902","pmcid":null,"openalex_id":"https://openalex.org/W4319008650","authors":[],"funders":[],"total_grants":0,"fwci":1.002,"citation_percentile":0.74906251,"influential_citations":0,"citation_trend":[{"year":2023,"count":1},{"year":2024,"count":2},{"year":2025,"count":1},{"year":2026,"count":2}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/2072-6694/15/3/945/pdf?version=1675328460","host_type":"journal"},{"url":"https://www.mdpi.com/2072-6694/15/3/945/pdf?version=1675328460","host_type":"publisher"},{"url":"https://www.mdpi.com/2072-6694/15/3/945/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/cancers15030945","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/36765902","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9913491","host_type":"repository"},{"url":"https://hal.u-pec.fr/hal-04240516","host_type":"repository"},{"url":"https://dx.doi.org/10.3390/cancers15030945","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9913491/pdf/cancers-15-00945.pdf","host_type":"repository"}],"fields_of_study":["Prostate Cancer Diagnosis and Treatment","Prostate Cancer Treatment and Research","Statistical Methods in Clinical Trials"],"mesh_terms":[],"keywords":["Medicine","Prostatectomy","Prostate cancer","Prostate","Internal medicine","Oncology","Radiation therapy","Risk stratification","Cancer","Gynecology","genomic prostate score","gleason score","risk assessment"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-09T13:56:31.263919Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}